Behnam Ahmadian Baghbaderani
Overview
Explore the profile of Behnam Ahmadian Baghbaderani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Babu S, Duvvuru H, Baker J, Switalski S, Shafa M, Panchalingam K, et al.
Biotechnol Rep (Amst)
. 2023 Feb;
37:e00784.
PMID: 36818379
Human induced pluripotent stem cells (iPSC) have demonstrated massive potentials for use in regenerative and personalized medicine due to their ability to expand in culture and differentiate into specialized cells...
2.
Dashtban M, Panchalingam K, Shafa M, Ahmadian Baghbaderani B
Methods Mol Biol
. 2020 May;
2286:179-198.
PMID: 32430594
The development of reprogramming technology to generate human induced pluripotent stem cells (iPSCs) has tremendously influenced the field of regenerative medicine and clinical therapeutics where curative cell replacement therapies can...
3.
Shafa M, Walsh T, Panchalingam K, Richardson T, Menendez L, Tian X, et al.
Int J Mol Sci
. 2019 Dec;
21(1).
PMID: 31877913
The clinical effectiveness of human induced pluripotent stem cells (iPSCs) is highly dependent on a few key quality characteristics including the generation of high quality cell bank, long-term genomic stability,...
4.
Shafa M, Panchalingam K, Walsh T, Richardson T, Ahmadian Baghbaderani B
Biotechnol Bioeng
. 2019 Sep;
116(12):3228-3241.
PMID: 31483482
Induced pluripotent stem cells (iPSCs) hold great potential to generate novel, curative cell therapy products. However, current methods to generate these novel therapies lack scalability, are labor-intensive, require a large...
5.
Shafa M, Yang F, Fellner T, Rao M, Ahmadian Baghbaderani B
Front Med (Lausanne)
. 2018 Mar;
5:69.
PMID: 29600249
The discovery of reprogramming and generation of human-induced pluripotent stem cells (iPSCs) has revolutionized the field of regenerative medicine and opened new opportunities in cell replacement therapies. While generation of...
6.
Ahmadian Baghbaderani B, Tian X, Cadet J, Shah K, Walde A, Tran H, et al.
PLoS One
. 2016 Sep;
11(9):e0161229.
PMID: 27606941
Human pluripotent stem cells (hPSCs) present an unprecedented opportunity to advance human health by offering an alternative and renewable cell resource for cellular therapeutics and regenerative medicine. The present demand...
7.
Ahmadian Baghbaderani B, Syama A, Sivapatham R, Pei Y, Mukherjee O, Fellner T, et al.
Stem Cell Rev Rep
. 2016 Jun;
12(4):394-420.
PMID: 27283945
We have recently described manufacturing of human induced pluripotent stem cells (iPSC) master cell banks (MCB) generated by a clinically compliant process using cord blood as a starting material (Baghbaderani...
8.
Ahmadian Baghbaderani B, Tian X, Neo B, Burkall A, Dimezzo T, Sierra G, et al.
Stem Cell Reports
. 2015 Sep;
5(4):647-59.
PMID: 26411904
The discovery of induced pluripotent stem cells (iPSCs) and the concurrent development of protocols for their cell-type-specific differentiation have revolutionized our approach to cell therapy. It has now become critical...